Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
494.80    9.40 (1.94%)
Bid:
494.60
Ask:
495.20
Spread: 0.60 (0.121%)
Market Cap: £1.34b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Alloy Surfaces contract awards

Today 07:00

RNS Number : 6592J
Chemring Group PLC
25 June 2026
 

FOR IMMEDIATE RELEASE 25 JUNE 2026

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

ALLOY SURFACES $300m IDIQ & $45m OTA US DEPARTMENT OF WAR CONTRACT AWARDS

 

In November 2025 the Group initiated a strategic review of its Philadelphia, USA-based pyrophoric airborne decoys business Alloy Surfaces Company ("ASC"). In the FY25 Report and Accounts ASC was classified as a discontinued operation due to insufficient order intake to support sustainable, continuous manufacturing. The Group has since been actively assessing its strategic options for the business.

 

The Group is pleased to announce that it has now signed agreements with the US Department of War ("DoW") to enable the resumption of sustained manufacturing operations at ASC.

 

A modification has been awarded to an Indefinite Delivery, Indefinite Quantity ("IDIQ") contract, funded under the Defense Production Act, to produce pyrophoric airborne decoys. The new award has a maximum value of $300 million over five years, with guaranteed minimum awards of $35 million per annum for the first three years. Deliveries under this IDIQ are expected to commence in early FY28. These critical defence assets will support the survivability of aviation platforms across the US Army, Air Force, Navy, Special Operations Command, and allied nations through Foreign Military Sales.

 

Under the terms of an Other Transaction Authority ("OTA") agreement, $45 million of Industrial Base Analysis and Sustainment program funds will also be received to launch the restart of manufacturing operations and the transfer to the DoW of intellectual property rights associated with ASC's pyrophoric decoys, with a modest amount received up front and the remaining amount spread over the next five years.

 

The Group is working with the DoW to assess the financial profile of these awards and will provide updated guidance at the year end. No impact on FY26 and FY27 performance is expected. For FY26 reporting ASC will be reclassified as a continuing operation with prior period comparatives re-presented accordingly. Land and buildings currently classified as assets held for sale will be reclassified to property, plant and equipment.

Michael Ord, Chemring Group Chief Executive, commented:

"As missile threats increase in scale and sophistication, air platform survivability remains mission‑critical. Today's announcement underscores the sustained and increasingly resilient demand we are seeing across our global countermeasures business and its ability to generate attractive returns for shareholders.

This award builds on our already strong order cover across Countermeasures & Energetics and reflects our customer's trust and confidence in the vital role Chemring plays in NATO's defence industrial base."

-ENDS-

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Group 07584 142665

Ollie Hoare 07817 458804

 

Cautionary statement

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE-250 listed global business that specialises in the manufacture of high technology products and the provision of services to the defence, security and aerospace markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTPPUCWQUPQPGC
Date   Source Headline
25th Jun 20267:00 amRNSAlloy Surfaces contract awards
19th Jun 202612:00 pmRNSHolding(s) in Company
18th Jun 20267:00 amRNSBlock listing Interim Review
18th Jun 20267:00 amRNSBlock listing update
18th Jun 20267:00 amRNSHolding(s) in Company
17th Jun 20268:49 amRNSHolding(s) in Company
16th Jun 20268:58 amRNSHolding(s) in Company
15th Jun 20262:21 pmRNSHolding(s) in Company
10th Jun 202610:31 amRNSHolding(s) in Company
3rd Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20267:02 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim results
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20262:36 pmRNSHolding(s) in Company
22nd May 20269:15 amRNSHolding(s) in Company
21st May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20263:46 pmRNSDirector/PDMR Shareholding
19th Mar 202611:00 amRNSHolding(s) in Company
4th Mar 20267:00 amRNSAppointment of non-executive director
2nd Mar 20269:15 amRNSTotal Voting Rights
20th Feb 20262:48 pmRNSResult of AGM
20th Feb 20267:00 amRNSAGM Update
16th Feb 20267:00 amRNSHolding(s) in Company
9th Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSTotal Voting Rights
23rd Jan 20264:41 pmRNSDirector/PDMR Shareholding
12th Jan 20261:35 pmRNSNotice of AGM
2nd Jan 202610:29 amRNSTotal Voting Rights
19th Dec 202511:53 amRNSHolding(s) in Company
19th Dec 202511:53 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSBlock listing Interim Review
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
15th Dec 20258:42 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20253:01 pmRNSAdditional Listing - Replacement
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 202512:41 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:38 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.